Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07535034) titled 'A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants' on April 10.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Crystalys Therapeutics
Condition:
Gout
Intervention:
Drug: Dotinurad
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: April 2026
Target Sample Size: 90
To know more, visit https://clinicaltrials.gov/study/NCT07535034
Disclaimer: Curated by HT Syndication....